Benzoazepin-oxy-acetic acid derivatives as PPAR-delta agonists used for the increase of HDL-C, lower LDL-C and lower cholesterol

A compound of Formula (Ia)

• wherein
• R1 and R2 are independently selected from the group consisting of H and C1-8alkyl, or R1, R2 and the carbon atom to which they are attached together may form C3-5cycloalkyl;
• R6 and R7 are independently selected from the group consisting of H, C1-3alkyl, halo, and halo substituted C1-3alkyl;
• R4 and R5 are independently selected from the group consisting of H and C1-8alkyl;
• and
• Q is selected from the group consisting of
• and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.

A compound of Formula (Ib)

• wherein
• R1 and R2are independently selected from the group consisting of H and CH3, or R1, R2 and the carbon atom to which they are attached together may form
• R4 and R5 are independently selected from the group consisting of H, CH3, and —CH2CH3;
• and
• Q is selected from the group consisting of
• and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.

A compound of Formula (Ic)

• R1, R2, and R4, are independently selected from the group consisting of H and CH3, or R1, R2 and the carbon atom to which they are attached together may form
• R5 is selected from the group consisting of H, CH3, and —CH2CH3;
• R7 is halo or halo substituted C1-3alkyl;
• and
• Q is selected from the group consisting of
• and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.

A compound of Formula (I)

• wherein:
• X is a covalent bond, O, or S;
• R1 and R2 are independently selected from the group consisting of H, C1-8alkyl, and substituted C1-8alkyl, or R1, R2 and the carbon atom to which they are attached together may form C3-7cycloalkyl;
• R3 is H;
• R4 and R5 are independently selected from the group consisting of H, halo, C1-8alkyl, C3-7cycloalkyl, C3-7cycloalkyl-C1-4alkyl, C3-7cycloalkyloxy-C1-4alkyl, C1-6alkoxy-C1-4 alkyl, C6-10aryl, heteroaryl, halo substituted C1-4alkyl, amino substituted C1-4alkyl, C6-10aryl substituted C1-4alkyl, heteroaryl substituted C1-4alkyl, cyano substituted C1-4alkyl, and hydroxy substituted C1-4alkyl;
• R6 and R7 are independently selected from the group consisting of H, halo, C1-3alkyl, halo substituted C1-3alkyl, C1-3alkoxy, and halo substituted C1-3alkoxy;
• n is 1;
• and
• Q is C6-10aryl;
• and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.

A compound of Formula (I)

• wherein:
• X is a covalent bond, O, or S;
• R1 and R2 are independently selected from the group consisting of H, C1-8alkyl, and substituted C1-8alkyl, or R1, R2 and the carbon atom to which they are attached together may form C3-7cycloalkyl;
• R3 is H;
• R4 and R5 are independently selected from the group consisting of H, halo, C1-8alkyl, C3-7cycloalkyl, C3-7cycloalkyl-C1-4alkyl, C3-7cycloalkyloxy-C1-4alkyl, C1-6alkoxy-C1-4 alkyl, C6-10aryl, heteroaryl, halo substituted C1-4alkyl, amino substituted C1-4alkyl, C6-10aryl substituted C1-4alkyl, heteroaryl substituted C1-4alkyl, cyano substituted C1-4alkyl, and hydroxy substituted C1-4alkyl;
• R6 and R7 are independently selected from the group consisting of H, halo, C1-3alkyl, halo substituted C1-3alkyl, C1-3alkoxy, and halo substituted C1-3alkoxy;
• n is 1 or 2;
• and
• Q is selected from the group consisting of
• and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.

A compound of Formula (I)

• wherein:
• X is a covalent bond, O, or S;
• R1 and R2 are independently selected from the group consisting of H, C1-8alkyl, and substituted C1-8alkyl, or R1, R2 and the carbon atom to which they are attached together may form C3-7cycloalkyl;
• R3 is H;
• R4 and R5 are independently selected from the group consisting of H, halo, C1-8alkyl, C3-7cycloalkyl, C3-7cycloalkyl-C1-4alkyl, C3-7cycloalkyloxy-C1-4alkyl, C1-6alkoxy C1-4 alkyl, C6-10aryl, heteroaryl, halo substituted C1-4alkyl, amino substituted C1-4alkyl, C6-10aryl substituted C1-4alkyl, cyano substituted C1-4alkyl, and hydroxy substituted C1-4alkyl;
• R6 and R7 are independently selected from the group consisting of H, halo, C1-3alkyl, halo substituted C1-3alkyl, C1-3alkoxy, and halo substituted C1-3alkoxy;
• n is 2;
• and
• Q is selected from the group consisting of
• and enantiomers, diastereomers, tautomers, or pharmaceutically acceptable salts thereof.